Beba Abadal, K., Walsh, M. A., Yachnis, A. T., Tran, D. D., & Ghiaseddin, A. P. (2017). Eleven Month Progression–Free Survival on Vemurafenib Monotherapy in a Patient With Recurrent and Metastatic BRAF V600E–Mutated Glioblastoma WHO Grade 4.
JCO Precision Oncology, (1), 1–5. doi:
10.1200/PO.17.00055
Cloughesy, T. F., Mochizuki, A. Y., Orpilla, J. R., Hugo, W., Lee, A. H., Davidson, T. B., … Prins, R. M. (2019). Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.
Nature Medicine, 25(3), 477–486. doi:
10.1038/s41591-018-0337-7
Combs, S. E., Rieken, S., Wick, W., Abdollahi, A., von Deimling, A., Debus, J., & Hartmann, C. (2011). Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back?
Radiation Oncology (London, England), 6, 115–115. doi:
10.1186/1748-717X-6-115
Daniel, P., Sabri, S., Chaddad, A., Meehan, B., Jean-Claude, B., Rak, J., & Abdulkarim, B. S. (2019). Temozolomide Induced Hypermutation in Glioma: Evolutionary Mechanisms and Therapeutic Opportunities.
Frontiers in Oncology, 9, 41–41. doi:
10.3389/fonc.2019.00041
Ferguson, S., & Lesniak, M. S. (2005). Percival Bailey and the classification of brain tumors.
Neurosurgical Focus FOC, 18(4). Retrieved from
https://thejns.org/focus/view/journals/neurosurg-focus/18/4/foc.2005.18.4.8.xml
Filley, A. C., Henriquez, M., & Dey, M. (2017). Recurrent glioma clinical trial, CheckMate-143: The game is not over yet.
Oncotarget, 8(53), 91779–91794. doi:
10.18632/oncotarget.21586
Kaley, T., Touat, M., Subbiah, V., Hollebecque, A., Rodon, J., Lockhart, A. C., … Hyman, D. M. (2018). BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study.
Journal of Clinical Oncology, 36(35), 3477–3484. doi:
10.1200/JCO.2018.78.9990
Karachi, A., Dastmalchi, F., Mitchell, D. A., & Rahman, M. (2018). Temozolomide for immunomodulation in the treatment of glioblastoma.
Neuro-Oncology, 20(12), 1566–1572. doi:
10.1093/neuonc/noy072
Kazda, T., Dziacky, A., Burkon, P., Pospisil, P., Slavik, M., Rehak, Z., … Lakomy, R. (2018). Radiotherapy of Glioblastoma 15 Years after the Landmark Stupp’s Trial: More Controversies than Standards?
Radiology and Oncology, 52(2), 121–128. doi:
10.2478/raon-2018-0023
Kessler, A. F., Frömbling, G. E., Gross, F., Hahn, M., Dzokou, W., Ernestus, R.-I., … Hagemann, C. (2018). Effects of tumor treating fields (TTFields) on glioblastoma cells are augmented by mitotic checkpoint inhibition.
Cell Death Discovery, 4, 12–12. doi:
10.1038/s41420-018-0079-9
Killela, P. J., Pirozzi, C. J., Healy, P., Reitman, Z. J., Lipp, E., Rasheed, B. A., … Bigner, D. D. (2014). Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas.
Oncotarget, 5(6), 1515–1525. doi:
10.18632/oncotarget.1765
Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., … Ellison, D. W. (2016). The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A summary.
Acta Neuropathologica, 131(6), 803–820. doi:
10.1007/s00401-016-1545-1
Marosi, C., & Preusser, M. (2017). Milestones of the last 10 years: CNS cancer.
Memo, 10(1), 18–21. doi:
10.1007/s12254-016-0309-x
Preusser, M., Lim, M., Hafler, D. A., Reardon, D. A., & Sampson, J. H. (2015). Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nature Reviews.
Neurology, 11(9), 504–514. doi:
10.1038/nrneurol.2015.139
Stoyanov, G. S., & Dzhenkov, D. L. (2018). On the Concepts and History of Glioblastoma Multiforme—Morphology, Genetics and Epigenetics.
Folia Medica, 60(1). Retrieved from
https://content.sciendo.com/view/journals/folmed/60/1/article-p48.xml
Cancer Genome Atlas Research Network. (2008). Comprehensive genomic characterization defines human glioblastoma genes and core pathways.
Nature, 455(7216), 1061–1068. doi:
10.1038/nature07385